JP Morgan Reiterates Neutral Rating on Pfizer Inc. (PFE)

Market Context

Pfizer Inc. operates in the Healthcare sector. The stock currently trades at $24.04 with a market capitalization of $146.7B. The stock has declined 2.2% over the past 52 weeks.

Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Pfizer Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Pfizer Inc.

Among the 10 most recent ratings: 1 Buy, 8 Hold, 1 Sell.

Date	Firm	Rating	Price Target
Jul 08, 2026	JP Morgan	Neutral	N/A
Jul 06, 2026	Cantor Fitzgerald	Neutral	N/A
Jul 06, 2026	HSBC	Hold	N/A
Jun 10, 2026	RBC Capital	Sector Perform	N/A
Apr 29, 2026	Citigroup	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View PFE Stock Page